Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
flowchart TD
events_adpd_2026_satellite_sym["AD/PD 2026 Satellite Symposia and Sponsors"]
events_adpd_2026_satellite_sym["Dates"]
events_adpd_2026_satellite_sym -->|"related to"| events_adpd_2026_satellite_sym
style events_adpd_2026_satellite_sym fill:#81c784,stroke:#333,color:#000
events_adpd_2026_satellite_sym["March"]
events_adpd_2026_satellite_sym -->|"related to"| events_adpd_2026_satellite_sym
style events_adpd_2026_satellite_sym fill:#81c784,stroke:#333,color:#000
events_adpd_2026_satellite_sym["Location"]
events_adpd_2026_satellite_sym -->|"related to"| events_adpd_2026_satellite_sym
style events_adpd_2026_satellite_sym fill:#81c784,stroke:#333,color:#000
events_adpd_2026_satellite_sym["Copenhagen"]
events_adpd_2026_satellite_sym -->|"related to"| events_adpd_2026_satellite_sym
style events_adpd_2026_satellite_sym fill:#81c784,stroke:#333,color:#000
style events_adpd_2026_satellite_sym fill:#4fc3f7,stroke:#333,color:#000
Satellite symposia at AD/PD 2026 provided in-depth educational sessions sponsored by pharmaceutical and biotechnology companies, offering detailed updates on specific therapeutic areas, clinical trial designs, and emerging treatment approaches["@adpd2026"].
Major Pharmaceutical Partners
Eisai Co., Ltd. ... Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
Mermaid diagram (expand to render)
Satellite symposia at AD/PD 2026 provided in-depth educational sessions sponsored by pharmaceutical and biotechnology companies, offering detailed updates on specific therapeutic areas, clinical trial designs, and emerging treatment approaches["@adpd2026"].
Major Pharmaceutical Partners
Eisai Co., Ltd.
Session Focus: Leqembi (lecanemab) real-world implementation and long-term outcomesKey Topics: ARIA management protocols, combination therapy approaches, biomarker monitoringPresentation Highlights: 36-month CLARITY-AD extension data, real-world effectiveness evidenceEli Lilly and Company
Session Focus: Donanemab development program and TRAILBLAZER-ALZ resultsKey Topics: Biomarker correlations with clinical outcomes, patient selection strategiesPresentation Highlights: Population expansion data, safety profile updatesRoche/Genentech
Session Focus: Tau therapeutics and anti-amyloid pipelineKey Topics: Gantenerumab long-term data, tau PET tracer developmentPresentation Highlights: Next-generation antibody engineering, reformulation approachesBiogen
Session Focus: Neurology portfolio and gene therapy programsKey Topics: Alzheimer's pipeline, Parkinson's gene therapy approachesPresentation Highlights: AAV-based delivery platforms, ASO development
Biotechnology Companies
Denali Therapeutics
Session Focus: LRRK2 inhibitor programs for Parkinson's diseaseKey Topics: DNL151 clinical results, BIIB122 development, genetic subpopulation analysisPresentation Highlights: Target engagement biomarkers, Phase 2 dose selectionAbbVie
Session Focus: Parkinson's disease therapeutics and dyskinesia managementKey Topics: ABBV-951 subcutaneous delivery, alpha-synuclein antibodiesPresentation Highlights: Motor complication management, continuous dopaminergic stimulationUCB Pharma
Session Focus: Alpha-synuclein modulation and CNS pipelineKey Topics: UCB0599 small molecule development, precision medicine approachesPresentation Highlights: Mechanism of action, patient stratification strategiesAlector/AbbVie Collaboration
Session Focus: TREM2-targeted immunotherapyKey Topics: AL002 agonist development, AL003 anti-TREM2 programsPresentation Highlights: Microglial modulation, neuroinflammation approaches
Diagnostic and Biomarker Companies
C2N Diagnostics
Session Focus: Fluid biomarker platformsKey Topics: PrecivityAD platform, p-tau217 assays, mass spectrometry approachesPresentation Highlights: Clinical utility data, regulatory qualification progressFujirebio
Session Focus: Lumipulse automated platformsKey Topics: Alzheimer biomarker panels, Parkinson's fluid markersPresentation Highlights: Assay standardization, global accessibilityRoche Diagnostics
Session Focus: Neurology biomarker portfolioKey Topics: Elecsys platform, amyloid and tau assaysPresentation Highlights: Cross-platform validation, clinical implementation
Thermo Fisher Scientific
Session Focus: Biomarker detection technologiesKey Topics: Ultra-sensitive assay platforms, multiplexing approachesCharles River Laboratories
Session Focus: Preclinical modelsKey Topics: Transgenic models, behavioral testing platformsCovance/Labcorp
Session Focus: Clinical trial servicesKey Topics: Central laboratory services, biomarker assay developmentSatellite Symposia Sessions
Educational Track Highlights
Morning Satellite Sessions (Daily 7:00-8:00 AM) Each morning featured industry-sponsored breakfast sessions:
Day 1: Tau pathology: From mechanisms to therapiesDay 2: Alpha-synuclein seed amplification in clinical practiceDay 3: Microglial modulation: New therapeutic frontiersDay 4: Biomarker-driven clinical trial designDay 5: Precision medicine in neurodegenerative diseasesAfternoon Satellite Sessions (Daily 5:30-6:30 PM) Evening symposia covered:
Day 1: Amyloid removal: Lessons from clinical experienceDay 2: LRRK2 inhibitors: Clinical development updatesDay 3: Gene therapy approaches: Current status and future directionsDay 4: Neuroinflammation: Targeting the complement systemDay 5: Combination therapy strategies: Rationale and evidenceSpecialized Workshops
Clinical Trial Design Workshop
Adaptive trial designs for neurodegenerative diseases
Biomarker enrichment strategies
Regulatory pathways for disease-modifying therapies
Biomarker Validation Workshop
Fluid biomarker standardization
PET tracer development pathways
Clinical validation methodologies
Patient Engagement Workshop
Clinical trial diversity
Remote monitoring approaches
Patient-reported outcomes integration
Industry-Funded Research Presentations
Investigator-Initiated Studies Company-sponsored investigators presented:
Real-world evidence from clinical practice
Post-hoc analyses of clinical trial data
Biomarker sub-studies and correlative science
Young Investigator Awards Industry-funded awards supported:
Travel grants for early-career researchers
Best abstract presentations
Mentorship programs
Booth Categories
Pharmaceutical Exhibitors Major pharmaceutical companies showcased:
Pipeline posters and presentations
Clinical trial enrollment information
Medical affairs consultations
Biotechnology Exhibitors Biotech companies displayed:
Research platforms and technologies
Collaboration opportunities
Investor relations materials
Service Providers Exhibition hall included:
Contract research organizations
Central laboratories
Imaging core facilities
Data management companies
Networking Events
Industry-Hosted Receptions Evening networking events featured:
Welcome reception (Day 1)
Sponsor showcase (Day 3)
Closing celebration (Day 5)
Partnering Meetings Structured partnering sessions allowed:
Academic-industry collaboration discussions
Licensing opportunity meetings
Clinical trial site selection
Key Takeaways
Pharmaceutical engagement remains strong — Major pharma continues significant investment in AD/PDBiomarker integration — Sponsors increasingly incorporating biomarkers in trial designsPrecision medicine focus — Genetic stratification and patient selection emphasizedCombination approaches — Growing interest in multi-target strategiesReal-world evidence — Post-approval data generation priority for sponsors
See Also
[AD/PD 2026 Conference](/events/adpd-2026)](/events)
[AD/PD 2026 Company Presentations](/events/adpd-2026-company-presentations)](/events)
[AD/PD 2026 Clinical Trial Updates](/events/adpd-2026-clinical-trials)](/events)
[AAIC 2026 Satellite Symposia](/events/aaic-2026)](/events)
[Events Index](/events/conference-index)
References
Unknown, AD/PD 2026 Conference Website (2026) Show full description